We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostic Microarray Characterizes Supernumary Chromosomes

By HospiMedica staff writers
Posted on 08 Nov 2006
A microarray has been developed that can rapidly characterize supernumary or marker chromosomes. More...
The information obtained from using this cytogenetic tool should lead to improved diagnosis and management of patients with marker chromosomes. In addition, high-resolution characterization of marker chromosomes will expand scientific knowledge of pericentromeric regions.

A diagnostic microarray for characterizing supernumerary marker chromosomes was constructed with over 900 bacterial artificial chromosome (BAC) clones, and represents, on average, more than 5.3 MB of each of the 43 unique pericentromeric regions of the human genome. Thus, the chromosomal origin of a marker can be determined together with the amount of euchromatin present.

The Signature MarkerChip, a diagnostic microarray for marker chromosomes, was developed by Signature Genomic Laboratories, LLC (Spokane, WA, USA). The chip is designed to analyze only the pericentromeric regions of the chromosomes to characterize marker chromosomes previously identified by chromosome analysis. The SignatureChip evaluates multiple areas of the genome for unbalanced microscopic and submicroscopic deletions and duplications.

A supernumary chromosome is a small chromosome containing a centromere occasionally seen in tissue culture, often in a mosaic state (present in some cells but not in others). A marker chromosome may be of little clinical significance or, if it contains material from one or both arms of another chromosome, may create an imbalance for whatever genes are present; assessment to establish the clinical significance, particularly if found in a fetal karyotype, is often difficult.

Clinicians are often required to use labor-intensive approaches to determine the origin and euchromatic content of a marker because traditional cytogenetic analysis is not always sufficient. Signature Genomic Laboratories recognized the need for a cytogenetic tool that could rapidly characterize marker chromosomes. Clinicians and cytogenetic laboratories can order the Signature MarkerChip whenever karyotype, fluorescent in situ hybridization (FISH), or general microarray analysis identifies a marker chromosome in an individual or a pregnancy.

If a marker chromosome does not contain euchromatin, the Signature MarkerChip will not detect the marker. In addition, low levels of mosaicism may not be detected by array comparative genomic hybridization (CGH).



Related Links:
Signature Genomic Laboratories

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Multi-Chamber Washer-Disinfector
WD 390
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.